Annual report 2020
To reflect the broad aspects of Novo Nordisk across therapy areas and geographies, Novo Nordisk introduced in 2019 a comprehensive approach describing the future growth aspirations of the company under the headline Strategic Aspirations 2025.
The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth.
Performance highlights
2025 strategic aspirations
2020 highlights
Adding value to society:
Environment:
2025 strategic aspirations
2020 highlights
Diabetes:
Biopharm:
Other serious chronic disease:
2025 strategic aspirations
2020 highlights
Diabetes sales increased by 8% at CER
Obesity sales increased by 3% at CER to DKK 5.6 billion
Biopharm sales increased by 1% at CER to DKK 18.9 billion
2025 strategic aspirations
Sales increased by 7% at CER, to DKK 126.9 billion
Free cash flow of DKK 28.6 billion and DKK 37 billion returned to shareholders
Read the full story in the report
Performance highlights
126,946
DKK million in net sales
54,125
DKK million in operating profit
42,138
DKK million in net profit
28,565
DKK million in free cash flow